This company has been acquired
Chembio Diagnostics (CEMI) Stock Overview
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CEMI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Chembio Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.24 |
| 52 Week Low | US$0.19 |
| Beta | 1.86 |
| 1 Month Change | 16.40% |
| 3 Month Change | 29.96% |
| 1 Year Change | -24.68% |
| 3 Year Change | -96.42% |
| 5 Year Change | -94.31% |
| Change since IPO | -99.70% |
Recent News & Updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Chembio Diagnostics (NASDAQ:CEMI) said it was awarded a $3.2M contract from the Centers for Disease Control and Prevention (CDC) to develop and validate a rapid point-of-care (POC) diagnostic test for syphilis. Chembio will develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II. The assay will be intended to simultaneously and separately detect treponemal and nontreponemal IgM and IgG antibodies, the company said in Sept. 6 press release. "We are excited to continue expanding our core sexually transmitted disease portfolio with the syphilis screen and confirm assay,” said Javan Esfandiari, chief science and technology officer, Chembio. CEMI +3.55% to $0.67 premarket Sept. 6Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Chembio Diagnostics (NASDAQ:CEMI) said it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. The company added that it is exploring the technical requirements for test development using its technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners. "We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are assessing the market needs, timing, regulatory pathway and investment required to develop a test," said Chembio's President and CEO Richard Eberly. CEMI +12.64% to $0.98 premarket Aug. 16Recent updates
Shareholder Returns
| CEMI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.1% | -5.5% | -0.9% |
| 1Y | -24.7% | -18.1% | 13.9% |
Return vs Industry: CEMI underperformed the US Medical Equipment industry which returned -0.1% over the past year.
Return vs Market: CEMI underperformed the US Market which returned -5.3% over the past year.
Price Volatility
| CEMI volatility | |
|---|---|
| CEMI Average Weekly Movement | 10.9% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CEMI's share price has been volatile over the past 3 months.
Volatility Over Time: CEMI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 188 | Richard Eberly | chembio.com |
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID 19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.
Chembio Diagnostics, Inc. Fundamentals Summary
| CEMI fundamental statistics | |
|---|---|
| Market cap | US$16.71m |
| Earnings (TTM) | -US$23.29m |
| Revenue (TTM) | US$49.52m |
Is CEMI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CEMI income statement (TTM) | |
|---|---|
| Revenue | US$49.52m |
| Cost of Revenue | US$45.65m |
| Gross Profit | US$3.88m |
| Other Expenses | US$27.17m |
| Earnings | -US$23.29m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 7.83% |
| Net Profit Margin | -47.03% |
| Debt/Equity Ratio | 104.4% |
How did CEMI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 09:40 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chembio Diagnostics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | Canaccord Genuity |
| Per Ostlund | Craig-Hallum Capital Group LLC |